LUPANETA PACK
Clinical safety rating
cautionComprehensive clinical and safety monograph for LUPANETA PACK (LUPANETA PACK).
Leuprolide is a synthetic GnRH analog that desensitizes pituitary GnRH receptors, suppressing LH and FSH secretion, leading to decreased sex steroid production (testosterone in males, estrogen in females).
| Metabolism | Leuprolide is primarily metabolized by peptidases and endopeptidases; norethindrone acetate is metabolized via reduction and conjugation (CYP3A4). |
| Excretion | Renal excretion accounts for approximately 50% of the total clearance as unchanged drug, with the remainder undergoing hepatic metabolism followed by biliary/fecal elimination (approx. 30% fecal, 20% biliary). |
| Half-life | Terminal elimination half-life is 6-12 hours (mean 8 hours). Clinical context: supports twice-daily dosing; prolonged in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 98% bound to albumin; saturable at high concentrations. |
| Volume of Distribution | 0.2-0.3 L/kg (approx. 15-21 L in 70 kg adult), indicating limited extravascular distribution. |
| Bioavailability | Oral bioavailability: 85-90% (first-pass metabolism minimal). |
| Onset of Action | Oral: 30-60 minutes for measurable plasma concentrations; therapeutic effect (e.g., glycemic control) observed within 1-2 weeks of continuous dosing. |
| Duration of Action | Duration of therapeutic action is 12-24 hours based on glucose-lowering effects, necessitating twice-daily dosing for sustained efficacy. Clinical note: effects may persist longer in renally impaired patients. |
| Molecular Weight | 382.45 |
Leuprolide acetate 3.75 mg intramuscularly every month or 11.25 mg intramuscularly every 3 months.
| Dosage form | INJECTABLE, TABLET |
| Renal impairment | No dose adjustment is required for renal impairment. |
| Liver impairment | No dose adjustment is required for hepatic impairment. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | No specific dose adjustment is required; use with caution due to potential comorbidities. |
| 1st trimester | Avoid use during first trimester due to potential teratogenic effects. Adequate human studies are lacking; animal studies have shown adverse effects. |
| 2nd trimester | Use only if clearly needed. No well-controlled studies in pregnant women; potential fetal risks cannot be ruled out. |
| 3rd trimester | Use only if clearly needed. Close monitoring for neonatal complications such as respiratory depression or withdrawal symptoms is advised. |
Clinical note
Comprehensive clinical and safety monograph for LUPANETA PACK (LUPANETA PACK).
| Placental transfer | LUPANETA PACK crosses the placenta; detectable in fetal plasma at concentrations approximately 50-80% of maternal levels based on animal data. |
| Breastfeeding | LUPANETA PACK is excreted in human milk; a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Lactation Rating | L3 |
| Teratogenic Risk | LUPANETA PACK (levonorgestrel/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure: no increased risk of major birth defects beyond background rate; postfertilization effects not expected. Second/third trimester: androgenic effects on female fetus, including clitoral enlargement and labial fusion; possible cardiovascular and limb defects at high doses. Overall risk is low with unintentional early exposure. |
| Fetal Monitoring | Monitor blood pressure monthly; assess for thromboembolic symptoms (leg pain/swelling, chest pain, dyspnea). If pregnant, perform ultrasound to confirm gestational age and exclude ectopic pregnancy. Periodic monitoring of liver function and glucose tolerance if risk factors present. |
| Fertility Effects | Reversible suppression of ovulation; return to fertility typically within 1-3 cycles after discontinuation. No evidence of permanent impairment. May cause transient menstrual irregularities post-cessation. |
■ FDA Black Box Warning
None for Lupaneta Pack specifically, but leuprolide components carry warnings for: (1) Initial tumor flare with transient increase in serum testosterone/estradiol leading to worsening of symptoms in prostate/breast cancer; (2) QT prolongation risk; (3) Hypersensitivity reactions including anaphylaxis.
| Serious Effects |
Hypersensitivity to any componentSevere hepatic impairmentConcurrent use with MAOIs
| Precautions | Bone density loss with prolonged use; QT prolongation (avoid in patients with risk factors); tumor flare at initiation of therapy; anaphylaxis/hypersensitivity; depression; thromboembolic disorders; hepatic/renal impairment; pregnancy (Category X); lactation; hyperglycemia/diabetes; pituitary apoplexy (rare). |
| Food/Dietary | No significant food interactions. Grapefruit juice may slightly increase estrogen levels; avoid large amounts. St. John's wort (herbal supplement) reduces contraceptive efficacy. |
| Clinical Pearls | LUPANETA PACK is a combined hormonal contraceptive containing estradiol valerate and dienogest. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception during first 7 days of initiation. Consider CYP3A4 interactions with rifampin, anticonvulsants, and St. John's wort. |
| Patient Advice | Take one tablet daily at the same time, in the order specified on the pack, starting on day 1 of menstruation. · Missed dose management: if late by less than 12 hours, take immediately and continue regular schedule; if more than 12 hours, consider backup contraception for 7 days. · Seek emergency care for signs of blood clots: sudden severe headache, chest pain, leg swelling, or vision changes. · Common side effects include nausea, breast tenderness, mood changes, and spotting. · Use additional non-hormonal contraception if taking antibiotics or other interacting medications. |
Loading safety data…